Home
ME
ME News

Latest 23andMe Holding Co. (ME) News on December 28, 2024

What’s Next for 23andMe?

Pharma Voice

18 days ago

What’s Next for 23andMe?

US Penny Stocks: 3 Picks With Market Caps Under $200M

Simply Wall St.

25 days ago

US Penny Stocks: 3 Picks With Market Caps Under $200M

Do Redditors Think That 23andMe Holding Co. (ME) Has a Big Upside Potential?

Insider Monkey

a month ago

Do Redditors Think That 23andMe Holding Co. (ME) Has a Big Upside Potential?

MT Newswires

a month ago

23andMe, Mirador Therapeutics Collaborate on Target Validation, Precision Medicine

23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador’s Precision Medicines for Immunology & Inflammation

GlobeNewswire

a month ago

23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador’s Precision Medicines for Immunology & Inflammation

23andMe to lay off more than 200 employees amid business struggles

MedTech Dive

a month ago

23andMe to lay off more than 200 employees amid business struggles

GuruFocus.com

a month ago

23andMe Holding Co (ME) Q2 2024 Earnings Call Highlights: Navigating Challenges with Strategic ...

Thomson Reuters StreetEvents

a month ago

Q2 2024 23andMe Holding Co. Earnings Call

23andMe is falling apart

Quartz

2 months ago

23andMe is falling apart

23andMe cuts 40% of its workforce

Fox Business

2 months ago

23andMe cuts 40% of its workforce

Struggling Genetic Testing Company 23andMe To Lay Off 40% Of Its Workforce, Discontinues All Therapeutic Programs

Benzinga

2 months ago

Struggling Genetic Testing Company 23andMe To Lay Off 40% Of Its Workforce, Discontinues All Therapeutic Programs

After its entire board resigned overnight, 23andMe will cut over 200 employees and its cancer research in an urgent bid to nurse the company back to health

Fortune

2 months ago

After its entire board resigned overnight, 23andMe will cut over 200 employees and its cancer research in an urgent bid to nurse the company back to health

23andMe cuts 40% of its workforce and discontinues therapeutics division

Associated Press Finance

2 months ago

23andMe cuts 40% of its workforce and discontinues therapeutics division

What’s happening with 23andMe? Mass layoffs and restructuring are the latest blow for the embattled DNA-testing company

FastCompany

2 months ago

What’s happening with 23andMe? Mass layoffs and restructuring are the latest blow for the embattled DNA-testing company

23andMe Lays Off 40% of Staff, Shuts Drug Development Business

The Wall Street Journal

2 months ago

23andMe Lays Off 40% of Staff, Shuts Drug Development Business

23andMe Reports Second Quarter Fiscal Year 2025 Financial Results

GlobeNewswire

2 months ago

23andMe Reports Second Quarter Fiscal Year 2025 Financial Results

23andMe cuts 40% of its workforce, discontinues all therapy programs

CNN Business

2 months ago

23andMe cuts 40% of its workforce, discontinues all therapy programs

MT Newswires

2 months ago

23andMe to Cut 40% of Workforce to Reduce Expenses, Examine Options for Assets

23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future

GlobeNewswire

2 months ago

23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future

CORRECTION - 23andMe to Report Q2 FY2025 Financial Results

GlobeNewswire

2 months ago

CORRECTION - 23andMe to Report Q2 FY2025 Financial Results

23andMe to Report Q2 FY2025 Financial Results

GlobeNewswire

2 months ago

23andMe to Report Q2 FY2025 Financial Results

23andMe turns to CFOs to fill director roles after mass board exit

CFO Dive

2 months ago

23andMe turns to CFOs to fill director roles after mass board exit

23andMe appoints three former CFOs as new directors—after the previous board all resigned

Fortune

2 months ago

23andMe appoints three former CFOs as new directors—after the previous board all resigned

23andMe Regains Compliance With Nasdaq Listing Requirements

GlobeNewswire

2 months ago

23andMe Regains Compliance With Nasdaq Listing Requirements

23andMe Appoints Three New Independent Directors to Board

GlobeNewswire

2 months ago

23andMe Appoints Three New Independent Directors to Board

Ancestry Says a 23AndMe Takeover Would Raise Antitrust Issues

Bloomberg

2 months ago

Ancestry Says a 23AndMe Takeover Would Raise Antitrust Issues

Ozempic and Alzheimer's, 23andMe's crisis, and Novo Nordisk wants a crackdown: Pharma news roundup

Quartz

2 months ago

Ozempic and Alzheimer's, 23andMe's crisis, and Novo Nordisk wants a crackdown: Pharma news roundup

The crisis at 23andMe, explained

Quartz

2 months ago

The crisis at 23andMe, explained

ASML's Latest Chapter in the Semiconductor Story

Motley Fool

2 months ago

ASML's Latest Chapter in the Semiconductor Story

SC US (TTGP), LTD. Acquires New Stake in 23andMe Holding Co

GuruFocus.com

2 months ago

SC US (TTGP), LTD. Acquires New Stake in 23andMe Holding Co

Explainer: 23andme is about to collapse – what happens to all that DNA data?

Medical Device Network

2 months ago

Explainer: 23andme is about to collapse – what happens to all that DNA data?

23andMe CEO says she can 'land this plane' after the entire board resigns

Quartz

2 months ago

23andMe CEO says she can 'land this plane' after the entire board resigns

Behind the scenes at 23andMe, questions about a star CEO

Fortune

2 months ago

Behind the scenes at 23andMe, questions about a star CEO

23andMe Introduces New Feature Helping African Americans Trace Their Roots to Post Slavery Communities in the South

GlobeNewswire

2 months ago

23andMe Introduces New Feature Helping African Americans Trace Their Roots to Post Slavery Communities in the South

23andMe’s entire board resigned on the same day. Founder Anne Wojcicki still thinks the startup is savable

Fortune

2 months ago

23andMe’s entire board resigned on the same day. Founder Anne Wojcicki still thinks the startup is savable

23andMe Announces Completion of 1-for-20 Reverse Stock Split

GlobeNewswire

2 months ago

23andMe Announces Completion of 1-for-20 Reverse Stock Split

Financial Times

2 months ago

Founder Anne Wojcicki races to rescue 23andMe

MT Newswires

3 months ago

23andMe Announces 1-for-20 Reverse Stock Split

GlobeNewswire

3 months ago

23andMe Announces Mathew Knowles as New Brand Ambassador

Millions urged to delete data from mail-order DNA test maker

The Telegraph

3 months ago

Millions urged to delete data from mail-order DNA test maker

Here’s how to delete your data from 23andMe if you’re worried about protecting your personal health information

Fortune

3 months ago

Here’s how to delete your data from 23andMe if you’re worried about protecting your personal health information

Legal Battle Brews Over 23andMe's Customer Data Breach Settlement And Arbitration Claimants

Benzinga

3 months ago

Legal Battle Brews Over 23andMe's Customer Data Breach Settlement And Arbitration Claimants

Investing.com

3 months ago

23andMe no longer open to third-party takeover bids - filing

23andMe CEO Wojcicki no longer open to third-party takeover proposals, filing shows

Reuters

3 months ago

23andMe CEO Wojcicki no longer open to third-party takeover proposals, filing shows

23andMe Launches New Genetic Report on Likelihood of Frequent Emotional Eating

GlobeNewswire

3 months ago

23andMe Launches New Genetic Report on Likelihood of Frequent Emotional Eating

23andMe Board Quits As CEO Of DNA Testing Company Plans To Go Private

Black Enterprise

3 months ago

23andMe Board Quits As CEO Of DNA Testing Company Plans To Go Private

What happened to 23andMe?

CNN Business

3 months ago

What happened to 23andMe?

23andMe directors resign as the CEO of the genetic-testing company seeks to take it private

Associated Press Finance

3 months ago

23andMe directors resign as the CEO of the genetic-testing company seeks to take it private

How 23andMe Went From Market Darling to Losing Its Entire Board

Barrons.com

3 months ago

How 23andMe Went From Market Darling to Losing Its Entire Board

23andMe’s independent board directors resign

MedTech Dive

3 months ago

23andMe’s independent board directors resign

Every single member of the board just resigned from DNA tester 23andMe

Fortune

3 months ago

Every single member of the board just resigned from DNA tester 23andMe

Tupperware, UAW-Stellantis, 23andme: 3 Stories In Focus

Yahoo Finance Video

3 months ago

Tupperware, UAW-Stellantis, 23andme: 3 Stories In Focus

MT Newswires

3 months ago

Sector Update: Health Care Stocks Steady Premarket Wednesday

Independent Board Members Of Penny Stock 23andMe Resign, Call Out CEO Anne Wojcicki For Not 'Actionable Proposal' Despite Ample Time

Benzinga

3 months ago

Independent Board Members Of Penny Stock 23andMe Resign, Call Out CEO Anne Wojcicki For Not 'Actionable Proposal' Despite Ample Time

MT Newswires

3 months ago

Market Chatter: 23andMe's Independent Directors Resign Over Weak Take-Private Offer

Investing.com

3 months ago

Landmark Fed decision in focus, futures edge higher - what's moving markets

23andMe Board Resigns in New Blow to DNA-Testing Company

The Wall Street Journal

3 months ago

23andMe Board Resigns in New Blow to DNA-Testing Company

23andMe independent directors quit board over unsatisfactory buyout plan from CEO

Reuters

3 months ago

23andMe independent directors quit board over unsatisfactory buyout plan from CEO

Independent Directors of 23andMe Resign from Board

GlobeNewswire

3 months ago

Independent Directors of 23andMe Resign from Board

23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study

GlobeNewswire

3 months ago

23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study

23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial

GlobeNewswire

3 months ago

23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial

23andMe settles data breach lawsuit for $30 million

Reuters

3 months ago

23andMe settles data breach lawsuit for $30 million

One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations

GlobeNewswire

4 months ago

One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations

23andMe CEO Wojcicki open to third-party takeover proposals for firm, filing shows

Reuters

4 months ago

23andMe CEO Wojcicki open to third-party takeover proposals for firm, filing shows

MT Newswires

4 months ago

23andMe Holding Investor Anne Wojcicki Open to Weighing Takeover Proposals

23andMe to Present Updates on Clinical Immuno-oncology Programs 23ME-00610 and 23ME-01473 at ESMO Congress 2024

GlobeNewswire

4 months ago

23andMe to Present Updates on Clinical Immuno-oncology Programs 23ME-00610 and 23ME-01473 at ESMO Congress 2024

MT Newswires

4 months ago

23andMe Holding's Subsidiary Offering Obesity Drugs Through Subscription-Based Weight Loss Program

Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program

GlobeNewswire

4 months ago

Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program

23andMe Reports First Quarter Fiscal 2025 Financial Results

GlobeNewswire

5 months ago

23andMe Reports First Quarter Fiscal 2025 Financial Results

MT Newswires

5 months ago

23andMe Rejects CEO's Take-Private Proposal

23andMe board rejects CEO Wojcicki’s take-private proposal

MedTech Dive

5 months ago

23andMe board rejects CEO Wojcicki’s take-private proposal

Genetic testing firm 23andMe rejects CEO's take-private offer

Reuters

5 months ago

Genetic testing firm 23andMe rejects CEO's take-private offer

Genetic testing firm 23andMe rejects CEO's take-private offer

Reuters

5 months ago

Genetic testing firm 23andMe rejects CEO's take-private offer

23andMe Special Committee responds to CEO’s take-private proposal

GlobeNewswire

5 months ago

23andMe Special Committee responds to CEO’s take-private proposal

MT Newswires

5 months ago

Sector Update: Health Care Stocks Rise in Afternoon Trading

MT Newswires

5 months ago

23andMe Receives Take-Private Proposal from Chief Executive

23andMe CEO proposes to take company private

MedTech Dive

5 months ago

23andMe CEO proposes to take company private

23andMe Announces CEO’s Take-Private Proposal

GlobeNewswire

5 months ago

23andMe Announces CEO’s Take-Private Proposal

23andMe CEO Wojcicki makes offer to take the firm private, filing shows

Reuters

5 months ago

23andMe CEO Wojcicki makes offer to take the firm private, filing shows

23andMe to Report Q1 FY2025 Financial Results

GlobeNewswire

5 months ago

23andMe to Report Q1 FY2025 Financial Results

Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research

GlobeNewswire

5 months ago

Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research

23andMe and Nightingale partner to pilot blood-based risk detection panel

Medical Device Network

6 months ago

23andMe and Nightingale partner to pilot blood-based risk detection panel

MT Newswires

6 months ago

23andMe to Offer Free Blood Testing for Members in Pilot Program

23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel

GlobeNewswire

6 months ago

23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel

MT Newswires

7 months ago

Update: 23andMe Under Scrutiny by UK, Canadian Privacy Regulators Over October Data Breach

MT Newswires

7 months ago

23andMe Under Scrutiny by UK, Canadian Privacy Regulators Over October 2023 Data Breach

BigBear.ai Stock: Buy, Sell, or Hold?

Motley Fool

7 months ago

BigBear.ai Stock: Buy, Sell, or Hold?

Indonesia's first Olympic gymnast encourages others to 'dream higher'

AFP

7 months ago

Indonesia's first Olympic gymnast encourages others to 'dream higher'

Where Will CrowdStrike Stock Be in 1 Year?

Motley Fool

7 months ago

Where Will CrowdStrike Stock Be in 1 Year?

Warren Buffett's Strategic Acquisition in Occidental Petroleum Corp

GuruFocus.com

7 months ago

Warren Buffett's Strategic Acquisition in Occidental Petroleum Corp

Insider Sale: EVP, CEO of Patient Direct, Perry Bernocchi, Sells Shares of Owens & Minor ...

GuruFocus.com

7 months ago

Insider Sale: EVP, CEO of Patient Direct, Perry Bernocchi, Sells Shares of Owens & Minor ...

A Look At The Intrinsic Value Of Deufol SE (HMSE:DE1)

Simply Wall St.

7 months ago

A Look At The Intrinsic Value Of Deufol SE (HMSE:DE1)

Chemring Group First Half 2024 Earnings: EPS: UK£0.045 (vs UK£0.067 in 1H 2023)

Simply Wall St.

7 months ago

Chemring Group First Half 2024 Earnings: EPS: UK£0.045 (vs UK£0.067 in 1H 2023)

VanEck Semiconductor ETF Is Riskier Than You Think

Motley Fool

7 months ago

VanEck Semiconductor ETF Is Riskier Than You Think

23andMe Launches New Genetic Report on Bipolar Disorder

GlobeNewswire

7 months ago

23andMe Launches New Genetic Report on Bipolar Disorder

Why 23andMe Stock Tumbled 10% on Tuesday

Motley Fool

7 months ago

Why 23andMe Stock Tumbled 10% on Tuesday

23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community

GlobeNewswire

7 months ago

23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community

23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting

GlobeNewswire

7 months ago

23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting

Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history

GlobeNewswire

7 months ago

Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history

23andMe Holding Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

7 months ago

23andMe Holding Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Share on Social Networks: